Kala Pharmaceuticals Inc Stock News

Cubist Systematic Strategies LLC reduced its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 65.0% in the second quarter, HoldingsChannel.com reports. The firm owned 44,169 shares of the companys stock after selling 82,085 shares during the period. Cubist Systematic Strategies LLCs holdings in Kala Pharmaceuticals were worth $234,000 at the end of the most []

Wedbush Securities Inc. trimmed its stake in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 42.8% during the third quarter, Holdings Channel.com reports. The fund owned 31,376 shares of the companys stock after selling 23,500 shares during the period. Wedbush Securities Inc.s holdings in Kala Pharmaceuticals were worth $82,000 at the end of the most recent quarter. Several []

Zacks Investment Research cut shares of Kala Pharmaceuticals (NASDAQ:KALA) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. []

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Equities researchers at Wedbush lowered their FY2021 earnings estimates for Kala Pharmaceuticals in a report issued on Tuesday, November 16th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($1.87) for the year, down from their prior forecast of ($1.80). Wedbush also issued estimates []

WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awar

Equities analysts forecast that Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Kala Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.42). Kala Pharmaceuticals posted earnings of ($0.55) []

Wall Street brokerages expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report earnings of ($0.45) per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Kala Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.42). Kala Pharmaceuticals posted earnings of ($0.55) per []

Kala Pharmaceuticals (NASDAQ:KALA) had its price target decreased by HC Wainwright from $11.00 to $9.00 in a research note issued to investors on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. Several other analysts have also recently weighed in on KALA. Zacks Investment Research upgraded shares of Kala Pharmaceuticals []

Kala Pharmaceuticals (NASDAQ:KALA) had its target price decreased by research analysts at HC Wainwright from $11.00 to $9.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage presently has a buy rating on the stock. HC Wainwrights price objective indicates a potential upside of 328.57% from the stocks []

Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Short squeeze penny stocks to watch right now. The post Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

Kala Pharmaceuticals Inc (NASDAQ: KALA) has acquired Combangio Inc, a private company developing regenerative biotherapies for severe ocular surface diseases.  Combangio is developing CMB-012, a s

Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?